Back to top
more

Emergent Biosolutions (EBS)

(Real Time Quote from BATS)

$14.29 USD

14.29
1,059,347

+0.48 (3.48%)

Updated Jul 25, 2024 10:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Emergent Biosolutions (EBS) Down 3.7% Since Last Earnings Report?

by Zacks Equity Research

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag

by Zacks Equity Research

The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.

Zacks.com featured highlights include Emergent Biosolutions, Western Digital, Thoughtworks Holding and DASAN Zhone Solutions.

by Zacks Equity Research

Emergent Biosolutions, Western Digital, Thoughtworks Holding and DASAN Zhone Solutions are part of the Zacks Screen of the Week article.

Rimmi Singhi headshot

4 Toxic Stocks More So Hazardous Amid Volatile Times

by Rimmi Singhi

Just like identifying stocks with growth potential, pinpointing toxic stocks and offloading them at the right time is crucial to guard one's portfolio from big losses. EBS, WDC, TWKS and DZSI are a few such toxic stocks.

Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services

Emergent Biosolutions (EBS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -2,016.67% and 10.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

AVEO (AVEO) delivered earnings and revenue surprises of 43.75% and 1.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo (DNA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Ginkgo's (DNA) third-quarter earnings call, investor focus is likely to be on the company's progress with its collaboration deals and the performance of its business units.

Perrigo (PRGO) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.

Emergent Biosolutions (EBS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral

by Zacks Equity Research

Emergent (EBS) completes the acquisition of worldwide rights to Tembexa, an FDA-approved smallpox oral antiviral for all ages, from Chimerix.

Emergent (EBS) Initiates Study on Lassa Virus Vaccine Candidate

by Zacks Equity Research

Emergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever.

Emergent Biosolutions (EBS) Down 20% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Emergent's (EBS) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Emergent's (EBS) second-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services.

Emergent Biosolutions (EBS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -236.51% and 16.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Emergent's (EBS) Anthrax Vaccine BLA Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts Emergent's (EBS) BLA seeking approval for its new anthrax vaccine, AV7909. A decision is expected in April next year.

Emergent (EBS) Stock Down as J&J Ends COVID-19 CDMO Contract

by Zacks Equity Research

Emergent (EBS) sends contract breach notice to J&J, following the latter's decision to end their contract for CDMO services for its COVID-19 vaccine. J&J also cites contract breach as the basis for termination.

Deciphera Pharmaceuticals, Inc. (DCPH) Up 4.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Company News for May 24, 2022

by Zacks Equity Research

Companies In The News Are: JPM, VMW, AVGO, EA, EBS.

The Zacks Analyst Blog Highlights Emergent BioSolutions, Chimerix and SIGA Technologies

by Zacks Equity Research

Emergent BioSolutions, Chimerix and SIGA Technologies have been included in this Analyst Blog.

Kinjel Shah headshot

Monkeypox Fears Drive Smallpox Antiviral Makers Higher

by Kinjel Shah

Emergent BioSolutions (EBS) stock was up almost 12% while SIGA Technologies (SIGA) rose 17.1% on Thursday.

Implied Volatility Surging for Emergent Biosolutions (EBS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Emergent Biosolutions (EBS) stock based on the movements in the options market lately.

Chimerix (CMRX) Plunges on Unfavorable Pipeline Updates

by Zacks Equity Research

The development of Chimerix's (CMRX) lead candidate, ONC201, gets delayed as the FDA states that data from the retrospective study is unlikely to support an approval. The company ends the DSTAT program.

Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Emergent's (EBS) first-quarter 2022 earnings miss estimates while sales beat the mark. EBS suspends its CDMO guidance for 2022 until it gets a better picture of the COVID-19 vaccine requirements.